Laxxon Medical Corporation announced today their invitation to participate as a private company in the 25th Annual Needham Growth Conference at the Lotte New York Palace Hotel on January 10-12, 2023.
Helmut Kerschbaumer, CEO/Chairman, and Alexander Ruckdaeschel, Chief Strategy Officer, will hold one-on-one meetings with institutional, private equity, and venture capital investors throughout the day on January 12, 2023.
About Laxxon Medical Corporation
Laxxon Medical is a pharma-technology company pioneering innovative 3D screen-printed pharmaceutical solutions through SPID®-Technology (Screen Printing Innovational Drug Technology), an additive 3D screen printing technology and manufacturing process. Laxxon Medical holds the exclusive worldwide rights to the use and application of SPID®-Technology for developing, manufacturing, and commercializing pharmaceutical dosage forms.
Investor Contact:
Alexander Ruckdaeschel Chief Strategy Director a.ruckdaeschel@laxxonmedical.com
Media Contact:
Frances Hoggard Communications Manager f.hoggard@laxxonmedical.com
Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients. We aim to establish SPID®-Technology as a manufacturing process with the individual and the pharmaceutical partner in mind.